Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results

Allogene Therapeutics (NASDAQ:ALLO) posted its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04, FiscalAI reports. The firm had revenue of $4.64 million for the quarter, compared to the consensus estimate of $0.00 million.

Here are the key takeaways from Allogene Therapeutics’ conference call:

• Allogene expanded the ALPHA3 trial to more than 80 active sites ahead of schedule and now expects approximately 100 sites by year-end, supporting enrollment and broader community access to cema-cel.
• Cema-cel received FDA RMAT and Fast Track designations for first-line consolidation in MRD-positive large B-cell lymphoma, which Allogene views as validation of the unmet need and the ALPHA3 approach.
• ALPHA3’s interim EFS analysis remains expected around mid-2027 despite faster site activation; management said statistical significance at the interim point would require overwhelming efficacy.
• ALLO-316 showed a 31% confirmed response rate in CD70-high renal cell carcinoma, with durable responses among five responders, but management acknowledged the small dataset and significant safety challenges.
• Enrollment in the ALLO-329 RESOLUTION autoimmune disease trial is proceeding rapidly, with clinical and translational data—including safety, efficacy, and dose-cohort findings—expected in the fourth quarter of 2026.

Allogene Therapeutics Stock Up 0.3%

Shares of ALLO stock traded up $0.01 during mid-day trading on Friday, reaching $1.99. 289,284 shares of the stock traded hands, compared to its average volume of 8,187,158. The stock’s fifty day simple moving average is $1.95 and its two-hundred day simple moving average is $2.12. Allogene Therapeutics has a 1-year low of $1.03 and a 1-year high of $4.46. The company has a market cap of $685.12 million, a price-to-earnings ratio of -2.96 and a beta of 0.48.

Analyst Ratings Changes

Several analysts have weighed in on ALLO shares. Weiss Ratings cut shares of Allogene Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. JPMorgan Chase & Co. upgraded Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a research report on Thursday, April 16th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.52.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALLO. AQR Capital Management LLC acquired a new stake in Allogene Therapeutics during the 1st quarter worth approximately $85,000. Goldman Sachs Group Inc. increased its position in Allogene Therapeutics by 177.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after acquiring an additional 3,747,397 shares during the period. Jane Street Group LLC raised its stake in shares of Allogene Therapeutics by 578.7% during the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock valued at $1,630,000 after acquiring an additional 952,158 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Allogene Therapeutics by 13.0% during the second quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock worth $4,289,000 after purchasing an additional 435,389 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Allogene Therapeutics by 14.0% during the second quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock worth $237,000 after purchasing an additional 25,628 shares during the period. Institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.